May 22, 2017
InnovaDerma launches haircare range, enters UK skincare market
InnovaDerma, a UK developer of life sciences, will launch a new haircare product range and its entry into the UK skincare market.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
May 22, 2017
Anavex presents new data for certain neuro-diseases tratment
Anavex Life Sciences, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, has announced new preclinical data for ANAVEX 2-73 in the neurodevelopmental disorders Angelman syndrome, Fragile X syndrome and Rett syndrome.
May 22, 2017
Celgene Corporation reports positive results for its multiple sclerosis drug testing
Celgene Corporation has announced that its phase III RADIANCE trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS), met the primary endpoint in reducing annualized relapse rate (ARR), compared to weekly interferon (IFN) β-1a (Avonex).
May 19, 2017
100 Healthy Years – Are Kids Prepared?
Merck, one of the worlds most renown science and technology companies, summoned experts from worlds organizations such as UN, UNICEF, UNAIDS, World Obesity Federation and McKinsey at the the company’s headquarters in Darmstadt, Germany, to discuss questions about the most urgent threats to our children’s long-term health, or what can be done both inside and outside the classroom? And how do schools, parents and communities share responsibility?
May 19, 2017
Arix bags $65 million in a B series investment round
Arix Bioscience on Friday said that its new business group, Iterum, has raised $65 million by closing a Series B investment round. “Arix is delighted to have led this $65m funding round comprising many of the biotech sector’s leading specialist investors,” said…
May 19, 2017
FDA expands Kalydeco indication for cystic fibrosis
The U.S. Food and Drug Administration (FDA) expanded the approved indication for Vertex Pharmaceuticals’ Kalydeco (ivacaftor) for the treatment of cystic fibrosis (CF).
May 18, 2017
Sobi to sell another rare disease drug in Saudi Arabia
The Saudi Food & Drug Authority (SFDA) has approved Swedish Orphan Biovitrum’s (Sobi) Elocta (efmoroctocog alfa), a recombinant human factor VIII Fc-fusion protein with an extended half-life, for the treatment of haemophilia A.
May 18, 2017
argenx raises approximately $100 million gross proceeds
argenx, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today the pricing of its initial public offering in the United States with anticipated gross proceeds totalling approximately $100 million from the sale of 5,865,000 American Depository Shares (“ADSs”), at a price to the public of $17.00 per ADS.
May 18, 2017
Oxford BioDynamics subsidiary signs exclusive Asia licence for breast cancer test
Oxford BioDynamics’s subsidiary Oxford BioDynamics Pte Limited, has signed an exclusive licence agreement with Nova Satra Diagnostics Asia Limited, to supply its proprietary products and reagents for the potential use in a non-invasive blood test to assist in the diagnosis of breast cancer, in complementation to current breast cancer screening procedures, across 13 territories in Asia.
May 18, 2017
FDA OK’s Vertex’s cystic fibrosis drug
U.S. Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ Kalydeco (ivacaftor) for use in people with cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.